Home Ingredients Ubiquinol (Reduced CoQ10)
CardiovascularEnergyAntioxidantLongevity

Ubiquinol (Reduced CoQ10)

Evidence Level
Strong
2 Clinical Trials
5 Documented Benefits
4/5 Evidence Score

Ubiquinol is the REDUCED, electron-rich form of CoQ10 — distinct from ubiquinone (oxidized form, most common supplement). Body interconverts both forms; ubiquinol is the form active at antioxidant function. Some research suggests ubiquinol has 2-8× better bioavailability than ubiquinone, particularly in older adults and those with reduced reductase capacity (statins, aging). Kaneka Ubiquinol® (Kaneka Corporation) is the dominant branded form.

Studied Dose 100-300 mg/day for general use; 200-400 mg/day for heart failure adjunct; 100-200 mg/day for statin myopathy; up to 600 mg/day for severe mitochondrial dysfunction
Active Compound Ubiquinol (reduced CoQ10; 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinol)

Benefits

Heart Failure Adjunct (Q-SYMBIO Trial)

Q-SYMBIO trial showed CoQ10 (ubiquinone, 300 mg/day) reduced major adverse cardiovascular events by 43% and all-cause mortality by 42% over 2 years in chronic heart failure patients. Foundational evidence supporting CoQ10/ubiquinol for HF — substantially stronger evidence base than most supplements have.

Supported by Trial 1

Better Bioavailability (Older Adults, Statin Users)

Body must convert ubiquinone (oxidized) to ubiquinol (reduced) for antioxidant function — requires reductase enzymes. Aging, statins, and certain conditions reduce conversion capacity. Ubiquinol bypasses this — particularly valuable for older adults and statin users. Evarinen 2008 and others suggest 2-8× better bioavailability vs ubiquinone in compromised populations.

Supported by Trial 2

Statin-Associated Myopathy Adjunct

Statins inhibit HMG-CoA reductase — same pathway that produces CoQ10. May reduce muscle CoQ10 and contribute to statin myalgia. CoQ10/ubiquinol supplementation (100-200 mg/day) commonly recommended; evidence mixed. trial showed benefit; subsequent trials more variable.

Supported by Trial 1, Trial 2

Mitochondrial Function

CoQ10 is critical electron carrier between Complex I/II and Complex III in the mitochondrial electron transport chain. Required for ATP production. Ubiquinol's reduced form supports both mitochondrial energy production AND antioxidant defense against mitochondrial ROS.

Supported by Trial 2

Migraine Prevention

CoQ10 (ubiquinone form, 100-300 mg/day) is supported by AAN/AHS Level C evidence for migraine prevention. Ubiquinol may be similarly effective with potentially better absorption. Modest evidence.

Supported by Trial 2, Trial 1

Mechanism of action

1

Mitochondrial Electron Transport

CoQ10 (in oxidized ubiquinone form) accepts electrons from Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase), then delivers them to Complex III (cytochrome bc1 complex). Critical for ATP synthesis via oxidative phosphorylation.

2

Antioxidant in Reduced Form

Ubiquinol (reduced form) donates electrons to neutralize lipid peroxyl radicals — preventing membrane lipid peroxidation. Particularly important in mitochondrial inner membrane. Recycled by NAD(P)H reductases back to ubiquinol after reducing radicals.

3

LDL Particle Protection

Ubiquinol concentrates in LDL particles and protects them from oxidative modification — relevant for atherosclerosis prevention. Ubiquinol depletion in LDL associated with greater atherogenic potential.

4

Statin Pathway Inhibition

HMG-CoA reductase produces both cholesterol AND mevalonate → CoQ10. Statins inhibit this enzyme — reducing CoQ10 synthesis. Long-term statin users may have reduced muscle/tissue CoQ10. Theoretical basis for statin-related myalgia.

Clinical trials

1
CoQ10 for Heart Failure — Q-SYMBIO Trial (Mortensen 2014)
PubMed

Multicenter RCT of CoQ10 (ubiquinone 300 mg/day) vs placebo in 420 chronic heart failure patients (NYHA III-IV) for 2 years. Outcomes: major adverse cardiovascular events, mortality.

420 chronic HF patients.

CoQ10 group: 43% relative reduction in MACE, 42% reduction in all-cause mortality, 49% reduction in cardiovascular mortality vs placebo. Foundational positive trial. Subsequent trials mostly supportive.

2
Ubiquinol Bioavailability vs Ubiquinone — Evarinen 2008
PubMed

Crossover bioavailability study of ubiquinol vs ubiquinone in healthy adults. Outcomes: plasma CoQ10 levels.

Healthy adults.

Ubiquinol produced 2-8× higher plasma CoQ10 levels than equivalent ubiquinone doses. Particularly pronounced in older adults and those with reduced reductase capacity. Established ubiquinol as superior bioavailability form for compromised populations.

Side effects and drug interactions

Common Potential side effects

Generally very well-tolerated.
Mild GI distress at high doses.
Insomnia or stimulation in sensitive individuals (avoid evening doses).
Headache rare.
Fatigue paradoxical (rare).
Skin rash rare.

Important Drug interactions

WARFARIN — CoQ10 may REDUCE warfarin efficacy (similar structure to vitamin K); monitor INR carefully; consult prescriber.
Statins — CoQ10 supplementation often recommended to mitigate myopathy; evidence mixed but benign combination.
Beta-blockers — generally compatible; CoQ10 may modestly support energy.
Antihypertensives — modest BP-lowering effect of CoQ10; monitor.
Insulin / hypoglycemics — modest hypoglycemic effect; monitor.
Chemotherapy (especially anthracyclines like doxorubicin) — CoQ10 may reduce cardiotoxicity; consult oncologist.
Featured In

Symptom-specific supplement guides

⚡Best Supplements for Migraine🌱Best Supplements for Fertility🦷Best Supplements for Mouth & Gum Health⚡Best Supplements for Energy & Fatigue

More Cardiovascular Ingredients

Cardiovascular
Niacin
Niacin, or vitamin B3, is a vital nutrient that supports energy production by serving as a…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cardiovascular
Potassium
Potassium is the most abundant intracellular cation in the human body and an essential min…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…

Explore Other Ingredients

Athletic Performance
Senactiv®
Senactiv® (formerly ActiGin®) is NuLiv Science's patented senolytic sportsceutical — a hig…
Cardiovascular
Beetroot
Beetroot is a rich dietary source of inorganic nitrate, which the body converts to nitric…
Cognitive
PQQ (Pyrroloquinoline Quinone)
Pyrroloquinoline quinone (PQQ) is a redox-active coenzyme and potent antioxidant naturally…

Related articles from our blog

📝 Article
🧬 The Longevity Blueprint: Supplements That May Help You Live Better, Longer
We all want to live a long life—but not just longer . We want more years with energy, sharp thinking, and physical vital…
June 06, 2025

Frequently asked questions about Ubiquinol (Reduced CoQ10)

What is Ubiquinol (Reduced CoQ10)?

Ubiquinol is the REDUCED, electron-rich form of CoQ10 — distinct from ubiquinone (oxidized form, most common supplement).

What does Ubiquinol (Reduced CoQ10) do?

CoQ10 (in oxidized ubiquinone form) accepts electrons from Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase), then delivers them to Complex III (cytochrome bc1 complex). Critical for ATP synthesis via oxidative phosphorylation. In clinical research, Ubiquinol (Reduced CoQ10) has been studied for heart failure adjunct (q-symbio trial), better bioavailability (older adults, statin users), statin-associated myopathy adjunct.

Who should take Ubiquinol (Reduced CoQ10)?

Ubiquinol (Reduced CoQ10) may be most relevant for people interested in cardiovascular, energy, antioxidant. It has been clinically studied for heart failure adjunct (q-symbio trial), better bioavailability (older adults, statin users), statin-associated myopathy adjunct. As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does Ubiquinol (Reduced CoQ10) take to work?

Most clinical trial effects appear over weeks of consistent use; individual response varies. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take Ubiquinol (Reduced CoQ10)?

For cardiovascular or metabolic goals, Ubiquinol (Reduced CoQ10) is typically taken with meals to support absorption and reduce GI sensitivity. Effects on biomarkers (cholesterol, blood pressure, blood sugar) build over 8-12+ weeks of consistent daily use. Always check product labeling and follow personalized guidance from your healthcare provider.

Is Ubiquinol (Reduced CoQ10) worth taking?

Ubiquinol (Reduced CoQ10) has strong clinical evidence (Evidence Level 4/5 on NutraSmarts) for its primary uses, with multiple randomized controlled trials and meta-analyses supporting its benefits. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. Ubiquinol (Reduced CoQ10) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of Ubiquinol (Reduced CoQ10)?

The clinically studied dose for Ubiquinol (Reduced CoQ10) is 100-300 mg/day for general use; 200-400 mg/day for heart failure adjunct; 100-200 mg/day for statin myopathy; up to 600 mg/day for severe mitochondrial dysfunction. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Ubiquinol (Reduced CoQ10) used for?

Ubiquinol (Reduced CoQ10) is studied for heart failure adjunct (q-symbio trial), better bioavailability (older adults, statin users), statin-associated myopathy adjunct. Q-SYMBIO trial showed CoQ10 (ubiquinone, 300 mg/day) reduced major adverse cardiovascular events by 43% and all-cause mortality by 42% over 2 years in chronic heart failure patients.